Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J. , May 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million , before
View HTML
Toggle Summary Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J. , May 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock.  J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers
View HTML
Toggle Summary Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration
Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders              Current Collaboration Extended to Include Three New Indications: Niemann-Pick Type C (NPC), Mucopolysaccharidosis Type IIIA (MPS
View HTML
Toggle Summary Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
CRANBURY, N.J. , May 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations.  He has
View HTML
Toggle Summary Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
CRANBURY, N.J. , May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14,
View HTML
Toggle Summary Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
1Q19 Galafold ® (m igalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19 Galafold Revenue of $34.0M and Early 2Q19 Momentum on Key Launch Metrics Maintaining FY19 Revenue Guidance of $160M-$180M and
View HTML
Toggle Summary Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Preclinical Studies Show Robust Uptake and Glycogen Reduction in Multiple Tissues, Including Brain and Spinal Cord Initial Validation for Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies Significant and Broad New Amicus Platform Technology with
View HTML
Toggle Summary Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
CRANBURY, N.J. , April 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2019 .
View HTML
Toggle Summary Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
CRANBURY, N.J. , April 15, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene & Cell
View HTML
Toggle Summary Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
New Intellectual Property Covers Composition of Matter and Manufacturing Method out to Mid-2030s CRANBURY, N.J. , March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the
View HTML